

APSAVD 2023
Asian-Pacific Society of Atherosclerosis and Vascular Disease

ORGANISED BY:



16TH CONGRESS OF THE ASIAN-PACIFIC SOCIETY OF ATHEROSCLEROSIS AND VASCULAR DISEASE

THEME

DIVING BEYOND THE ATHEROSCLEROSIS EXPANSE

 **8-9 Sep 2023**
FRI - SAT • 8 AM - 6 PM

 **Vertical @ CCEC,**
Kuala Lumpur Malaysia



HIGHLIGHT PROGRAMME

- Latest Therapy on Lipid Management
- Addressing ASCVD Risks
- Public Forum
- Non-LDL Targets
- Basic Science/Clinical Research and Awards

		EARLY BIRD (7 AUGUST 2023)	REGULAR (7 SEPT 2023)	ONSITE (8 & 9 SEPT 2023)
Non-Malaysian	APSAVD Member	USD 377	USD 424	USD 477
	Non- APSAVD Member	USD 424	USD 477	USD 530
Malaysian	Doctor	MYR 1,272	MYR 1,378	MYR 1,590
	Allied Health	MYR 1,060	MYR 1,272	MYR 1,484
	Student	MYR 530	MYR 636	MYR 742

INVITED SPEAKER

Ahmad Izzuanudin Ismail
 Alan Fong
 Borge Nodestgaard
 Brian Tomlinson
 Chan Siew Pheng
 Chan Wah Keong
 Chua Seng Keong
 Edward Janus
 Feisul Mustafa
 Gyu-Chul Oh
 Hapizah Nawawi
 Jeyamalar Rajadurai
 Kausik Ray
 Kazuaki Negishi
 Lim Lee Ling

Mohd Al-Baqlish Mohd Firdaus
 Muhammad Iqbal Abdul Hafidz
 Osamu Baba
 Raul Santos
 Richard O'Brien
 Robert Hegele
 Sang-Hyun Kim
 Sazzli Kasim
 Shizuya Yamashita
 Siti Fatimah Badlishah Sham
 Sunita Bavanandan
 Syadi Zuhdi
 Ta Chen Su
 Tan Chen Ting
 Zubin Othman Ibrahim

PROGRAMME - AT - GLANCE

DAY 1, 8 SEPT 2023

Time	Summit 1	Summit 2
0900 - 1030	Symposium 1A: Latest Evidence in Lipid Therapy	Symposium 1B: Vulnerable Plaque and Imaging (ISCP APSAVID Joint Symposium)
	Familial Hypercholesterolemia: Recent and Novel Therapies	Chemokine receptor targeting PET imaging of atherosclerosis
	Updates on Therapy for Lowering Triglycerides and Lp(a)	Imaging in Vulnerable Plaque
	LDL Lowering and ASCVD Trials: What's New?	Evidence in Targeting Inflammation
1030 - 1045	Coffee Break, Booth & Poster Visit	
1045 - 1100	Opening Ceremony	
1100 - 1145	Akira Yamamoto Plenary Lecture	
1145 - 1245	APSAVID YIA Oral Presentation (Clinical)	APSAVID YIA Oral Presentation (Basic Science)
1245 - 1430	Sponsored Lunch Symposium	
1430 - 1600	Symposium 2A: ASCVD Disease Burden from Different Regions (APSAVID EAS Joint Symposium)	Symposium 2B: Updates on Lipid Guideline from Around the World
	Australia	ESC and ACC
	Denmark	Malaysia CPG on Lipid 2023
	Malaysia	How to Use Lipid Guidelines in Daily Practice
1600 - 1730	Symposium 3A: Addressing ASCVD Risk in Patients with Chronic Kidney Disease	Symposium 3B: 2023 International Guidance on Best Practices for FH Patients (IAS APSAVID Joint Symposium)
	Burden of ASCVD in CKD patients	Detection and Diagnosis
	Characteristic Features of Dyslipidemia and its Treatment in CKD Patients	Cascade Screening
	Treatment options in CKD patients	Mx and Implementation Strategies
1745 - 1845	APSAVID AGM	

DAY 2, 9 SEPT 2023

Day 2, 9 Sept 2023		
Time	Summit 1	Summit 2
0830 - 1000	Symposium 4A: Dyslipidaemic patients - EAS JAS APSAVID Joint symposium	Symposium 4B: TG/NAFLD/NASH
	EAS-FHSC Registry - Lessons Learnt	Metabolic dysfunction associated fatty liver disease
	Assessing cardiovascular risk in Asian patients	Management of Patients with High TG
	2022 Japan Atherosclerosis Society (JAS) Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia (FH)	Outcomes of Patients Treated for High TG
1000 - 1045	Moderated Poster Presentation for YIA	
	Session: 5 minutes Presentation + 2 minutes Q&A	
	Total Presenters: 6	
	Coffee Break, Booth & Poster Visit	
1045 - 1215	Symposium 5A: Triggering Plaque Rupture	Symposium 5B: Diabetes and ASCVD- Joint Symposium APSAVID- KSoLA
	Stress and cardiovascular deaths- pattern and relationship	Risk prediction fallacy in dysglycaemic individuals
	Sleep patterns and the risk of heart disease	Mortality reduction where it really matters - the role of SGLT2i and GLPs
	Air pollution exposure and CV disease	Impact of diabetes on coronary atherosclerosis: its prevalence and clinical outcomes according to diabetic control
1215 - 1300	Philip Ding Plenary Lecture	
1300 - 1430	Lunch Symposium 2 (Novartis)	
1430 - 1600	Symposium 6A: Special Forum ASCVD and the public	Symposium 6B: Targeting Non-LDL to Reduce Risk of ASCVD
		Lipoprotein(a)
		TBC
		Triglycerides
1600 - 1730	Symposium 7A: Is There a Role for Antiplatelet in ASCVD in 2023?	Symposium 7B: LDL Targets
	The History of Antiplatelet Therapy	Evidence and Practice Gap in LDL Therapy
	Current Evidence in ASCVD Risk Management	Assessing Risk and Initiation of Treatment
	Questions Unanswered in Antiplatelet Therapy	Role of Risk Enhancers in the Clinic
1730 - 1800	Closing & Prize Giving Ceremony	

FOR MORE INFO:

- ✉ apsavd2023@anderesfourdy.events
- 🌐 www.apsavd2023.com
- ☎ **+6010 981 1491 (Azwin)**
- ☎ **+6017 529 1491 (Munchees)**

